IAS News and Literature Updates:
July/August 2017
From the President's Desk:
Yuji Matsuzawa

The World Heart Federation (WHF) 2nd Global Summit on Circulatory Health was held in Singapore, July 12-13, 2017, and we are very pleased that the IAS Federation Chair of the Asia-Pacific Region, Shizuya Yamashita, was invited to speak in the workshop on access to essential and affordable medicines and technologies as the representative of the International Atherosclerosis Society (IAS).
Prof. Yamashita joined over 100 leaders of global, regional, and national organizations which met to discuss how to create the case for urgent action in the fight against circulatory diseases. The overall objective was to build on the United Nations goal of a 25% reduction in premature non-communicable disease mortality by 2025, Goal 3 of the Sustainable Development Goals (SDGs), and in anticipation of the forthcoming United Nations High-Level Meeting on Noncommunicable Diseases (UN HLM on NCDs) in September 2018.
David Wood, President of the World Heart Federation, stated, "Without swift adoption of prevention and intervention strategies, current worldwide trends indicate increased global death and disability from preventable circulatory diseases. The global health community must act now with a greater sense of urgency if we are to contend with the world’s number one killer.”


Through a series of workshops, panel discussions, and plenary sessions moderated by Richard Horton from The Lancet, a consensus was rapidly reached on the need to collectively support the implementation of the 25 by 25 agenda at both the national and global level through the following actions:

Also included in this Newsletter:

Toronto, Canada
June 9 - 12, 2018

XVIII International Symposium on Atherosclerosis

In the News: 

Novel Proteomic Approaches to Identify Circulating Cardiovascular Biomarkers

By: José Tuñón, Luis Blanco-Colio, Óscar Lorenzo, Jesús Egido, and José Luis Martín-Ventura

Atherothrombosis is among the leading causes of mortality and disability in the world. Although new therapies have been developed in the last years, our patients continue to have cardiovascular events, suggesting that we need new therapeutic targets. However, there is an additional issue: our patients do not share a similar evolution. While some of them may experience recurrent cardiovascular events, other may have an isolated acute event followed by long periods of clinical stability. Thus, it follows that it would be ideal to identify patients at high risk of progression of the disease in order to concentrate on them the most intensive therapies.

Circulating biomarkers may be helpful identifying high-risk patients, given that blood is permanently exchanging molecules with the vascular wall and then it can provide us with information about vascular biology.

View Complete Commentary <

Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease

By: Andreas Kousios, Panayiotis Kouis, and Andrie G Panayiotou

Cardiovascular disease (CVD) is the leading cause of death in end-stage renal disease patients (ESRD). Chronic kidney disease (CKD), even from its early asymptomatic stages and proteinuria, increases the risk for CVD substantially. Traditional CVD risk factors are highly prevalent in CKD patients; however, the use of traditional risk factor scores underestimates the CVD risk in patients with CKD.

Subclinical Atherosclerosis and the Pathophysiologic Role of MMPs in CKD
The atherosclerotic changes of the arterial wall that precede CVD events, termed subclinical atherosclerosis, include intima-media thickness and artery plaques and constitute a hallmark of atherosclerosis. These can be measured by ultrasonography and provide a surrogate endpoint of cardiovascular outcomes.

> View Complete Commentary <


September 8-9, 2017

The 6th International Congress on Lipid Metabolism & Atherosclerosis
ICoLA 2017
Seoul, Korea

View Meeting Website

September 14-15, 2017

Intersociety Session SAL-IAS-SAC: Synergy to Deal with the Challenges XIV Annual Meeting of the Argentine Society of Lipids: Chemistry, biology, genetic: two decades
Buenos Aires, Argentina

View Meeting Website

October 18-19, 2017

V Symposium of the Iberoamerican Network Association on Familial Hypercholesterolemia
Buenos Aires, Argentina

Scientific Program of the Symposium

November 12, 2017

Joint AHA-IAS Session: Visceral Adiposity and Cardiovascular Disease
AHA Meeting Scientific Session 2017
 Anaheim, CA

View Meeting Website 

November 23-25, 2017

XXXVIII Congreso Chileno de Medicina Interna 2017“Controversias en Medicina Interna, una oportunidad de aprendizaje”
Vina del Mar, Chile

View Meeting Website

For a complete listing of all Member Society meetings and educational activities

Please Click Here


The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission: Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, Ono Pharmaceutical Co., Ltd., OSLA - Oman Society of Lipids and Atherosclerosis, Otsuka Pharmaceutical Co., Ltd., Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College.

>> Back To Top <<
IAS Newsletter Editors
Website Editorial Board
Scott M. Grundy, MD, PhD
Dallas, TX, USA

Associate Editors
Stefano Bellosta, PhD
Milan, Italy
Emanuela Folco, PhD
Milan, Italy
Ann Jackson, MBA
Houston, TX, USA

Website & Newsletter Editors
Elena Colombo
Milan, Italy
Yelonda Williams, BA
Dallas, TX, USA


You are a valued member of the International Atherosclerosis Society. You are receiving this email because you opted in at our website - www.athero.org

Unsubscribe <<Email Address>> from this list.

Our mailing address is:
International Atherosclerosis Society
Fondazione Giovanni Lorenzini Medical Science Foundation
viale Piave 35
Milan, Italy 20129

Add us to your address book

Copyright (C) 2017 International Atherosclerosis Society All rights reserved.

Forward this email to a friend
Update your profile